DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,502 | -30.5% | 218,194 | -0.6% | 0.05% | -27.0% |
| Q2 2023 | $6,476 | +26.9% | 219,448 | -0.9% | 0.06% | +23.5% |
| Q1 2023 | $5,103 | -11.1% | 221,500 | +7.3% | 0.05% | -15.0% |
| Q4 2022 | $5,742 | -99.9% | 206,500 | +16.5% | 0.06% | -6.2% |
| Q3 2022 | $5,438,000 | -1.4% | 177,196 | +3.3% | 0.06% | +18.5% |
| Q1 2022 | $5,517,000 | -27.9% | 171,496 | 0.0% | 0.05% | -20.6% |
| Q4 2021 | $7,648,000 | -11.6% | 171,496 | 0.0% | 0.07% | -16.0% |
| Q3 2021 | $8,652,000 | -36.9% | 171,496 | -1.9% | 0.08% | -35.7% |
| Q2 2021 | $13,711,000 | +73.6% | 174,796 | +26.4% | 0.13% | +61.5% |
| Q1 2021 | $7,897,000 | -28.1% | 138,296 | +5.4% | 0.08% | -29.1% |
| Q4 2020 | $10,989,000 | +133.8% | 131,196 | 0.0% | 0.11% | +107.5% |
| Q3 2020 | $4,701,000 | +48.2% | 131,196 | 0.0% | 0.05% | +39.5% |
| Q2 2020 | $3,172,000 | +38.1% | 131,196 | 0.0% | 0.04% | +18.8% |
| Q1 2020 | $2,297,000 | – | 131,196 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |